Page 23 - GTM-2-2

Global Translational Medicine Use of cardio biomarker in diagnosis of AMI

4.9. Heart-type fatty acid-binding protein (H-FABP) 4.12. Growth differentiation factor-15

Tissues with lower expression of H-FABP include the Growth differentiation factor-15 (GDF-15) is a distant
brain, kidney, skeletal tissue, adrenal gland, and mammary member of transformation growth factor (TGF) and can
gland tissues, as well as blastocysts [38,39] . H-FABP is a be activated in response to tissue damage. Multiple types of
valuable tool for assessing patients with chest pain in the cardiovascular cells have the potential to produce GDF-15
emergency department, and its concentration is elevated under pathological circumstances. GDF-15 levels are
as early as 30 min after myocardial injury. Peaking at 6–8 h higher in the blood and are related to increased cardiac
and reverting to baseline after 24 h, H-FABP is sensitive metabolic risk factors. The fact that GDF-15 is drastically
enough for the early detection of AMI. This protein exhibits elevated in CVD and that the level of GDF-15 is directly
an 82% negative predictive value in testing . associated with the frequency of CVD [47-49] increases the
[40]
possibility that it might be an useful disease biomarker.
4.10. B-type natriuretic peptide According to a meta-analysis, high levels of GDF-15 were
One of the most well-known indicators of biomechanical associated with a higher risk of death in patients with
stress is B-type natriuretic peptide (BNP) . Produced in CVD [49,50] . GDF-15 further supports NT-pro-BNP and
[16]
response to the tense cardiomyocytes in the ventricle , CRP as well as standard hazard factors in the detection
[40]
BNP binds to and activates receptors, lowering central of acute coronary syndrome (ACS), and it is a standalone
venous pressure, natriuresis, and systemic vascular indicator of all-cause mortality in ACS patients [51,52] .
resistance. Research has shown that BNP offers predictive 4.13. Suppression of tumorigenicity 2
information after myocardial infarction . Although this
[41]
biomarker has a half-life, it is released, along with the When hearts are being strained mechanically, the blood
N-terminal (NT)-pro-BNP, a peptide that is considerably levels of suppression of tumorigenicity 2 (ST-2), an IL-1-
[16]
stronger in serum and is simple to test. The biology of this receptor-like protein, were found to be raised . In the IL-1
substance is still not well understood, particularly with receptor family, there are two isoforms of ST-2: Soluble
[53]
regard to the post-translational metabolism of the peptides, (ST2L) and transmembrane (ST2) . It was later discovered
which may interfere with the precise measurement of BNP that ST2 targets IL-33, a kind of interleukin that only
levels . develops when myocytes are under biomechanical stress
[42]
and seem to play a cardioprotective role . Cardiomyocyte
[54]
4.11. Atrial natriuretic peptide hypertrophy caused by phenylephrine and angiotensin II
was shown to be significantly decreased by IL-33 in studies
Both atrial natriuretic peptide (ANP) and BNP have using mice. The connection between ST-2 and IL-33 may
comparable neurohormonal effects and secretory
profiles after AMI. ANP levels have been precisely also alleviate the burden of the atheroma. However, it has a
weak correlation with NT-pro-BNP after an AMI and both
measured in other studies, although with mixed results. of these biomarkers are predictive of cardiac failure or death
It has been established that N-ANP is connected to 6 months after a myocardial infarction. A study found that
late mortality after AMI [43] . Interference and analyte the IL-33/ST-2 pathway is the therapeutic target of AMI .
[55]
unreliability commonly affect ANP assays [44] . ANP was Level of ST2 is higher in both autoimmune diseases and
deemed to give meager prognostic information due to acute asthma. It is necessary to verify the specificity of
unsatisfactory outcomes. Nevertheless, the identification ST-2 for cardiac tissue stretching before applying it at the
of a new midregional (MR)-pro-ANP fragment [45] . The clinical settings (Table 1 and Figure 2) .
[56]
peptide is much more stable than ANP. MR-pro-ANP is
at least as good at predicting mortality and heart failure 5. Methods for detecting and diagnosing
as MR-pro-ANP due to the test epitopes being positioned AMI
internally on the pro-ANP molecules (and hence
stability to exoprotein activity) as NT-pro-BNP [46] . When 5.1. Colorimetric assay for diagnosing AMI
MR-pro-ANP levels were divided into quartiles, the The principles of conventional ELISA testing are also applied
highest quartile was associated with a hazard ratio (HR) to colorimetric immunoassays. Specific binding occurs
of 3.87 (vs. NT-pro-BNP’s HR 3.25), including a higher between an antigen or antibody and its complementary
likelihood of mortality at follow-up. The area under the antibody or antigen. A secondary antibody or antigen that
curve (AUC) of the receiver operating characteristic is enzyme-labeled is added during the detection stage to
(ROC) curve for each biomarker was similar (0.83). trigger an enzymatic reaction when it binds to the primary
Thus, MR-pro-ANP is a powerful predictor of adverse antibody. The outcome of this reaction is an appreciable color
outcomes after an AMI. change, as a result of the transformation of the substrate

Volume 2 Issue 2 (2023) 5 https://doi.org/10.36922/gtm.0403